1.	Vaccination of Patients With Stage IV Melanoma With Dendritic Cells Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 21 to 75 Sponsor: Other Protocol IDs: Baylor IRB #005-065-02, NCT00125749
2.	Phase II Study of Vaccine Therapy Comprising Autologous Dendritic Cells Pulsed With Allogeneic Melanoma Tumor Cell Lysates (IDD-3) in Patients With Unresected Stage IIIB or IIIC or Stage IV Melanoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-0408080-01, IDM-DC-MEL-202, NCT00107159
3.	Dendritic Cells in Lung Cancer Phase: Phase II Type: Treatment Status: Completed Age: Over 18 Sponsor: Other Protocol IDs: Dendric cells in lungcancer, NCT00442754